title: Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?
abstract: BACKGROUND
  Renal dysfunction has recently been described as a potential complication of tritherapy with telaprevir (TVR) in patients with chronic hepatitis C. This study aimed to identify predictive factors for and consequences of TVR-associated renal dysfunction.
  
  
  METHODS
  A retrospective-prospective study was carried out in 96 patients with chronic hepatitis C, genotype 1, treated with TVR-based tritherapy in 2012-2013, in whom regular serum creatinine measurements were performed during the first 12 weeks of treatment. The patients received standard doses of peginterferon, ribavirin and TVR (2250 mg/day). The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease formula.
  
  
  RESULTS
  eGFR decreased significantly from baseline at weeks 4, 8 and 12, the mean maximum decrease being 22.0±23.6 ml/min, with a significant correlation between baseline and minimum eGFR (r=0.58, P<10), stronger between week 2 and minimum eGFR in the subgroup of 62 patients in whom creatinine measurement was performed at week 2. Thirteen patients had an eGFR below 60 ml/min during treatment. Age and baseline eGFR were independent predictors of eGFR below 60 ml/min in the entire population, and only week 2 eGFR when available. The decrease in haemoglobin was significantly correlated with the decrease in eGFR. Age, baseline haemoglobin and the maximum variation in eGFR were independent predictors for minimum haemoglobin. The patients with decreased eGFR had more severe anaemia, and received more blood transfusions and erythropoietin. Renal dysfunction regressed in all patients after stopping TVR.
  
  
  CONCLUSIONS
  The reversible decrease in eGFR in patients receiving TVR-containing tritherapy can be predicted early, possibly allowing measures aimed at preventing anaemia.
authors: aHepatogastroenterology Unit, Centre Hospitalier, Perpignan bHepatogastroenterology Unit, Centre Hospitalier, Montfermeil cHepatogastroenterology Unit, Centre Hospitalier, Montélimar dHepatogastroenterology Unit, Centre Hospitalier Régional d'Orléans, Orléans eHepatogastroenterology Unit, Centre Hospitalier de Corbeil, Corbeil fHepatogastroenterology Unit, Centre Hospitalier, Pau gHepatogastroenterology Unit, Centre Hospitalier, Créteil, France hHepatogastroenterology Unit, Hôpital de Jolimont, Haine-Saint-Paul, Belgium.
authors: André-Jean
authors: AJ
authors: Rémy
authors: Bruno
authors: B
authors: Lesgourgues
authors: Bernard
authors: B
authors: Nalet
authors: Xavier
authors: X
authors: Causse
authors: Jean
authors: J
authors: Henrion
authors: Jacques
authors: J
authors: Denis
authors: Ramuntxo
authors: R
authors: Arotçarena
authors: Hervé
authors: H
authors: Hagège
authors: Alexandre
authors: A
authors: Pariente
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000139:chemically induced; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006454:Hemoglobins / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000009:adverse effects* / Q000627:therapeutic use; D011237:Predictive Value of Tests; D011446:Prospective Studies; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D012189:Retrospective Studies; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors
chemical_list: D000998:Antiviral Agents; D006454:Hemoglobins; D016898:Interferon-alpha; D009842:Oligopeptides; D012254:Ribavirin; C486464:telaprevir